Therapeutic modalities in small cell lung cancer: a paradigm shift after decades of quiescence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic modalities in small cell lung cancer: a paradigm shift after decades of quiescence

Published:2022-02-21 Issue:5 Volume:23 Page:583-597
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

El Sayed Rola¹^ORCID,El Darsa Haidar²

Affiliation:

1. Department of Hematology-Oncology, Division of Thoracic Oncology, Centre Hospitalier de l’ Université de Montréal, Université de Montréal, Montréal, Quebec, Canada

2. Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2042515

Reference132 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Small Cell Lung Cancer

3. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

4. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study;Journal of Cancer;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP